Investor Lawsuits Target Multiple Firms

The legal actions against Bath & Body Works stem from allegations that the company misled investors about its growth strategy. The class-action lawsuit, filed in the Southern District of Ohio, claims that between June 2024 and November 2025, the company's focus on adjacent product categories like men's, hair, and lip products was failing to grow its customer base, a fact that was not properly disclosed. This alleged lack of transparency led to significant stock drops when the company revealed disappointing financial results. On August 28, 2025, the stock fell 6.9%, and on November 20, 2025, it plummeted another 24.8% after the company cut its sales guidance and admitted its strategy had not grown the total customer base. Investors now have until March 16, 2026, to move the court to be appointed as lead plaintiff. For Smart Digital Group, the allegations are more severe, involving claims of a market manipulation and fraudulent promotion scheme. The lawsuit alleges that between May and September 2025, the company failed to disclose that it was the subject of a promotional campaign based on misinformation from impersonators of financial professionals, and that insiders may have been coordinating to dump shares. The scheme unraveled on September 26, 2025, when the company's stock price collapsed by 86.4%. Shortly after, the SEC suspended trading of the stock, citing "potential manipulation." The deadline for investors to file as lead plaintiff in this case is also March 16, 2026. Hub Group's legal troubles are rooted in accounting errors. On February 5, 2026, the transportation and logistics provider announced it would need to restate its financial statements for the first three quarters of 2025. The reason given was the discovery of an error that resulted in the understatement of purchased transportation costs and accounts payable. This news sent the company's stock down over 18% on February 6, 2026. Aquestive Therapeutics is facing scrutiny after a setback with the U.S. Food and Drug Administration. On January 9, 2026, the company revealed the FDA had identified deficiencies in its New Drug Application for Anaphylm, a sublingual film for treating severe allergic reactions. Following the announcement, Aquestive's stock price dropped by more than 37%. Law firms are now investigating whether the company made false or misleading statements to investors prior to this disclosure.